Ritlecitinib side effects

The GST enzymes involved in the metabolism of Ritlecitinib (Ritlecitinib) include cytoplasmic GST A1/3, M1/3/5, P1, S1, T2, Z1 and microsomal GST 1/2/3. The CYP enzymes involved in this process include CYP3A, CYP2C8, CYP1A2 and CYP2C9. The safety of ritexitinib was evaluated in three randomized, placebo-controlled clinical trials and one long-term trial in subjects 12 years of age and older with alopecia areata (including alopecia totalis and alopecia universalis).

Reported in ≥1% of subjects, and the incidence was higher than placebo for up to 24 weeks, adverse reactions include headache, diarrhea, acne, rash, urticaria, folliculitis, pyrexia, atopic dermatitis, dizziness, herpes zoster, stomatitis, and common laboratory abnormalities include increased blood creatine phosphokinase (CPK), decreased red blood cell count, decreased platelet count, and elevated liver enzymes. In clinical trials, ritixitinib has been administered in single oral doses of up to 800 mg. Adverse effects were comparable to those observed at lower doses, and no specific toxicities were noted. Pharmacokinetic (PK) data from a single oral dose of 800 mg (inclusive) in healthy adult volunteers indicate that more than 90% of the administered dose is expected to be eliminated within 48 hours.

There is no specific antidote for ritexitinib overdose, treatment should be symptomatic and supportive, and patients should be monitored for signs and symptoms of adverse reactions. Since ritexitinib is a new drug for the treatment of alopecia areata, it has not yet been marketed in China and has not been included in medical insurance. Its price has not yet been learned. For specific prices and drug details, you can consult a medical consultant.